Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study)

English version

Autoři: Catriona Waitt ^aff001; Catherine Orrell ^aff004; Stephen Walimbwa ^aff002; Yashna Singh ^aff004; Kenneth Kintu ^aff002; Bryony Simmons ^aff005; Julian Kaboggoza ^aff002; Mary Sihlangu ^aff004; Julie-Anne Coombs ^aff004; Thoko Malaba ^aff006; Josaphat Byamugisha ^aff007; Alieu Amara ^aff001; Joshua Gini ^aff001; Laura Else ^aff001; Christie Heiburg ^aff004; Eva Maria Hodel ^aff001; Helen Reynolds ^aff001; Ushma Mehta ^aff006; Pauline Byakika-Kibwika ^aff002; Andrew Hill ^aff001; Landon Myer ^aff006; Mohammed Lamorde ^aff002; Saye Khoo ^aff001
Působiště autorů: Department of Molecular & Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom ^aff001; Infectious Disease Institute, Makerere University College of Health Sciences, Kampala, Uganda ^aff002; Royal Liverpool University Hospital, Liverpool, United Kingdom ^aff003; Desmond Tutu HIV Foundation, Cape Town, South Africa ^aff004; Department of Medicine, Imperial College London, London, United Kingdom ^aff005; Division of Epidemiology and Biostatistics and Centre for Infectious Diseases Epidemiology & Research, School of Public Health & Family Medicine, University of Cape Town, Cape Town, South Africa ^aff006; Department of Obstetrics and Gynaecology, Makerere University College of Health Sciences, Kampala, Uganda ^aff007
Vyšlo v časopise: Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study). PLoS Med 16(9): e32767. doi:10.1371/journal.pmed.1002895
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1002895

Souhrn

Background

The global transition to use of dolutegravir (DTG) in WHO-preferred regimens for HIV treatment is limited by lack of knowledge on use in pregnancy. Here we assessed the relationship between drug concentrations (pharmacokinetics, PK), including in breastmilk, and impact on viral suppression when initiated in the third trimester (T3).

Methods and findings

In DolPHIN-1, HIV-infected treatment-naïve pregnant women (28–36 weeks of gestation, age 26 (19–42), weight 67kg (45–119), all Black African) in Uganda and South Africa were randomised 1:1 to dolutegravir (DTG) or efavirenz (EFV)-containing ART until 2 weeks post-partum (2wPP), between 9^th March 2017 and 16^th January 2018, with follow-up until six months postpartum. The primary endpoint was pharmacokinetics of DTG in women and breastfed infants; secondary endpoints included maternal and infant safety and viral suppression. Intensive pharmacokinetic sampling of DTG was undertaken at day 14 and 2wPP following administration of a medium-fat breakfast, with additional paired sampling between maternal plasma and cord blood, breastmilk and infant plasma.

No differences in median baseline maternal age, gestation (31 vs 30 weeks), weight, obstetric history, viral load (4.5 log₁₀ copies/mL both arms) and CD4 count (343 vs 466 cells/mm³) were observed between DTG (n = 29) and EFV (n = 31) arms. Although DTG C_trough was below the target 324ng/mL (clinical EC90) in 9/28 (32%) mothers in the third trimester, transfer across the placenta (121% of plasma concentrations) and into breastmilk (3% of plasma concentrations), coupled with slower elimination, led to significant infant plasma exposures (3–8% of maternal exposures). Both regimens were well-tolerated with no significant differences in frequency of adverse events (two on DTG-ART, one on EFV-ART, all considered unrelated to drug). No congenital abnormalities were observed. DTG resulted in significantly faster viral suppression (P = 0.02) at the 2wPP visit, with median time to <50 copies/mL of 32 vs 72 days. Limitations related to the requirement to initiate EFV-ART prior to randomisation, and to continue DTG for only two weeks postpartum.

Conclusion

Despite low plasma DTG exposures in the third trimester, transfer across the placenta and through breastfeeding was observed in this study, with persistence in infants likely due to slower metabolic clearance. HIV RNA suppression <50 copies/mL was twice as fast with DTG compared to EFV, suggesting DTG has potential to reduce risk of vertical transmission in mothers who are initiated on treatment late in pregnancy.

Trial registration

clinicaltrials.gov NCT02245022

Klíčová slova:

Biology and life sciences – Organisms – People and places – Population groupings – Anatomy – Medicine and health sciences – Microbiology – Medical microbiology – Microbial pathogens – Pathology and laboratory medicine – Pathogens – Physiology – Women's health – Maternal health – Birth – Labor and delivery – Obstetrics and gynecology – Pregnancy – Pharmacology – Nutrition – Viral pathogens – Immunodeficiency viruses – HIV – Retroviruses – Lentivirus – Viruses – RNA viruses – Pharmacokinetics – Body fluids – Blood – Blood plasma – Diet – Virology – Viral transmission and infection – Viral load – Age groups – Children – Families – Beverages – Milk – Infants – Breast milk

Zdroje

1. Myer L, Phillips TK, Hsiao NY, Zerbe A, Petro G, Bekker LG, et al. Plasma viraemia in HIV-positive pregnant women entering antenatal care in South Africa. J Int AIDS Soc. 2015;18:20045. doi: 10.7448/IAS.18.1.20045 26154734; PubMed Central PMCID: PMC4495612.

2. Meyers K, Qian H, Wu Y, Lao Y, Chen Q, Dong X, et al. Early Initiation of ARV During Pregnancy to Move towards Virtual Elimination of Mother-to-Child-Transmission of HIV-1 in Yunnan, China. PLoS One. 2015;10(9):e0138104. doi: 10.1371/journal.pone.0138104 26407096; PubMed Central PMCID: PMC4583380.

3. Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutierrez F, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369(19):1807–18. doi: 10.1056/NEJMoa1215541 24195548.

4. Min S, Sloan L, DeJesus E, Hawkins T, McCurdy L, Song I, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS. 2011;25(14):1737–45. Epub 2011/07/01. doi: 10.1097/QAD.0b013e32834a1dd9 21716073.

5. Meintjes G, Black J, Conradie F. Southern African HIV Clinicians Society adult antiretroviral therapy guidelines: Update on when to initiate antiretroviral therapy. S Afr Med J. 2015;16(1):4.

6. The Integrated National Guidelines on Antiretroviral Therapy, Prevention of Mother to Child Transmission of HIV and Infant and Young Child Feeding. The Republic of Uganda. 2012. http://library.health.go.ug/publications/hivaids/integrated-national-guidelines-antiretroviral-therapy-prevention-mother-child, Accessed 17 July 2019

7. Penchala SD, Fawcett S, Else L, Egan D, Amara A, Elliot E, et al. The development and application of a novel LC-MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2016;1027:174–80. doi: 10.1016/j.jchromb.2016.05.040 27290668.

8. Gini J, Penchala SD, Amara A, Challenger E, Egan D, Waitt C, et al. Validation and clinical application of a novel LC-MS method for quantification of dolutegravir in breast milk. Bioanalysis. 2018. Epub 2018/11/20. doi: 10.4155/bio-2018-0085 30450920.

9. Gallagher RM, Kirkham JJ, Mason JR, Bird KA, Williamson PR, Nunn AJ, et al. Development and inter-rater reliability of the Liverpool adverse drug reaction causality assessment tool. PLoS One. 2011;6(12):e28096. doi: 10.1371/journal.pone.0028096 22194808; PubMed Central PMCID: PMC3237416.

10. Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. Br J Psychiatry. 1987;150:782–6. 3651732.

11. Min S, Song I, Borland J, Chen S, Lou Y, Fujiwara T, et al. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother. 2010;54(1):254–8. Epub 2009/11/04. AAC.00842-09 [pii] doi: 10.1128/AAC.00842-09 19884365; PubMed Central PMCID: PMC2798521.

12. Cottrell ML, Hadzic T, Kashuba AD. Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet. 2013;52(11):981–94. doi: 10.1007/s40262-013-0093-2 23824675; PubMed Central PMCID: PMC3805712.

13. Electronic Medicines Compendium. Tivicay film-coated tablets. Summary of product characteristics. 2018. Available from: https://www.medicines.org.uk/emc/product/5248/smpc.

14. Mulligan N, Best BM, Wang J, Capparelli EV, Stek A, Barr E, et al. Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV. AIDS. 2018;32(6):729–37. doi: 10.1097/QAD.0000000000001755 29369162; PubMed Central PMCID: PMC5854536.

15. Bollen P, Colbers A, Schalkwijk S, Velthoven-Graafland K, Konopnicki D, Weizsacker K, et al., editors. First report of dolutegravir unbound plasma concentrations during pregnancy in HIV-positive women. 19th International Workshop on Clinical Pharmacology of Antiviral Therapy; 2018; Baltimore, USA.

16. Buckoreelall K, Cressey TR, King JR. Pharmacokinetic optimization of antiretroviral therapy in pregnancy. Clin Pharmacokinet. 2012;51(10):639–59. Epub 2012/09/29. doi: 10.1007/s40262-012-0002-0 23018528.

17. Kobbe R, Schalkwijk S, Dunay G, Eberhard JM, Schulze-Sturm U, Hollwitz B, et al. Dolutegravir in breast milk and maternal and infant plasma during breastfeeding. AIDS. 2016;30(17):2731–3. doi: 10.1097/QAD.0000000000001259 27782968.

18. Pain JB, Le MP, Caseris M, Amiel C, Lassel L, Charpentier C, et al. Pharmacokinetics of dolutegravir in a premature neonate after HIV treatment intensification during pregnancy. Antimicrob Agents Chemother. 2015;59(6):3660–2. doi: 10.1128/AAC.00173-15 25845873; PubMed Central PMCID: PMC4432130.

19. Zash R, Makhema J, Shapiro RL. Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception. N Engl J Med. 2018;379(10):979–81. doi: 10.1056/NEJMc1807653 30037297.

20. WHO. Statement on DTG. Geneva: World Health Organisation; 2018. https://www.who.int/medicines/publications/drugalerts/Statement_on_DTG_18May_2018final.pdf, accessed 01 July 2019

21. Zash R, Jacobson DL, Diseko M, Mayondi G, Mmalane M, Essex M, et al. Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study. Lancet Glob Health. 2018;6(7):e804–e10. doi: 10.1016/S2214-109X(18)30218-3 29880310; PubMed Central PMCID: PMC6071315.

22. Hill A, Clayden P, Thorne C, Christie R, Zash R. Safety and pharmacokinetics of dolutegravir in HIV-positive pregnant women: a systematic review. J Virus Erad. 2018;4(2):66–71. 29682297; PubMed Central PMCID: PMC5892677.

23. Garcia PM, Kalish LA, Pitt J, Minkoff H, Quinn TC, Burchett SK, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med. 1999;341(6):394–402. doi: 10.1056/NEJM199908053410602 10432324.